Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Share-based Compensation data on file, last reported at $30000.0 in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $30000.0, down 25.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $113.1 million (down 6.59% YoY), and the FY2025 annual result was $153.0 million, down 3.16% from the prior year.
• Share-based Compensation fell to $30000.0 in Q1 2026 per RARE's latest filing, from $37.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $41.6 million in Q3 2024 and troughed at $30000.0 in Q1 2026.
• A 5-year average of $31.6 million and a median of $35.8 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 32.5% in 2022, then plunged 99.89% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $29.4 million in 2022, then increased by 14.18% to $33.5 million in 2023, then grew by 19.74% to $40.1 million in 2024, then decreased by 6.65% to $37.5 million in 2025, then plunged by 99.92% to $30000.0 in 2026.
• Business Quant data shows RARE's Share-based Compensation at $30000.0 in Q1 2026, $37.5 million in Q4 2025, and $37.0 million in Q3 2025.